Jushi Holdings (JUSHF) Notes Payables (2023 - 2026)
Jushi Holdings' (JUSHF) quarterly Notes Payables came in at $139000.0 in Q1 2026, down 53.04% on a QoQ basis from $296000.0 in Q4 2025.
Jushi Holdings (JUSHF) Notes Payables (2023 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 4 years of Notes Payables data on file, last reported at $139000.0 in Q1 2026.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $139000.0 in Q1 2026; TTM through Mar 2026 was $139000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $296000.0, changed N/A from the prior year.
- Notes Payables for Q1 2026 stood at $139000.0, down from $296000.0 in the prior quarter.
- Over the last five years, Notes Payables for JUSHF reached as high as $7.2 million in Q1 2024 and fell as low as $139000.0 in Q1 2026.
- Historically, Notes Payables has averaged $2.1 million across 4 years, with a median of $1.2 million in 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 139,000.00 |
| Dec 31, 2025 | 296,000.00 |
| Sep 30, 2024 | 156,000.00 |
| Jun 30, 2024 | 2.08 Mn |
| Mar 31, 2024 | 7.22 Mn |
| Dec 31, 2023 | 2.42 Mn |